With failed NIH Covid-19 study, Humanigen CEO points to competitors' flops before FDA nods
Humanigen is going back to the drawing board for its antibody meant to thwart so-called cytokine storms as the drug has failed an NIH Covid-19 therapeutics study.
Citing the rise in Covid-19 cases and deaths, as well as the need for variant-agnostic treatments, CEO Cameron Durrant told Endpoints News the biotech will likely look to externally-funded platform studies of its drug, lenzilumab, going forward in the hopes of getting the drug to patients outside of clinical trials, despite already being told no by the FDA last September for an EUA request.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.